CASE DISCUSSION
HRD Evaluation in 4 types of Cancers
Presented India by Dr. Shibichakravarthy KannanViews
43,773
Credit Points
Learning Hours
CPD Points
CME Points
Courses Completed
Case Description
HRD (Homologous Recombination Deficiency) evaluation plays a crucial role in assessing the genetic characteristics and treatment strategies for various types of cancers. In breast cancer, it helps identify patients with DNA repair defects that may benefit from targeted therapies. In ovarian cancer...
Case Summary
- The discussion begins with a real-world patient scenario involving confusion over which genetic test to order for breast cancer, highlighting the evolution of BRCA testing to include HRR gene mutation panels and HRD tests. The lack of Indian companies offering HRD tests until recently, with Myriad Genetics' MyChoice CDx being the primary option, is emphasized. The importance of tumor-agnostic biomarkers and the shift away from organ-specific biomarkers like EGFR in lung cancer is discussed, noting that biomarkers are increasingly found across multiple cancer types due to shared oncogenesis mechanisms.
Speaker Profile
Dr. Shibichakravarthy Kannan
Precision Oncology, Founder & CEO in Oncophenomics Inc., HyderabadDisclosures
Assimilate requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant financial relationships for anyone with the ability to control the content of this educational activity have been reviewed and mitigated. Others involved in the planning of this activity have no relevant financial relationships.